Table 1.
Reports of r/r NKTCL treated with immunotherapy.
| Author | Study | No. | Treatment | Response | PFS |
|---|---|---|---|---|---|
| Tao et al. (8) | Phase 2 | 28 | Sintilimab | 19 (CR + PR) | – |
| Kim et al. (9) | Phase 2 | 21 | Avelumab | 5 CR, 3 PR | 2.7 m (median) |
| Kim et al. (10) | Retrospective | 14 | Pembrolizumab | 5 CR, 1 PR | – |
| Kwong et al. (11) | Case series | 7 | Pembrolizumab | 5 CR, 2 PR | – |
| Li et al. (12) | Case series | 7 | pembrolizumab | 2 CR, 2 PR | 4.8 m (median) |
| Chan et al. (13) | Case series | 3 | Nivolumab | 1 CR | – |
| Klee et al. (14) | Case reporta | 1 | Pembrolizumab + radiotherapy | CR | >2 y |
| Kim et al. (15) | Case report | 1 | Pembrolizumab + haploidentical HSCT | CR | >6 m |
| Asif et al. (16) | Case report | 1 | Pembrolizumab + radiotherapy | CR | 4 m |
| Lai et al. (17) | Case report | 1 | Pembrolizumab | CRb | >8 m |
CR, complete response; PR, partial response; m, month; y, year. aThis case had an early-stage disease; bThis was a radiological complete response. The plasma EBV-DNA was persistent positive.